Citations

Clear

6273 citation(s) found for "To, Andrew".

Practice Parameters for the Use of Autotitrating Continuous Positive Airway Pressure Devices for Titrating Pressures and Treating Adult Patients with Obstructive Sleep Apnea Syndrome: An Update for 2007
Aurora, R. Nisha , Brown, Terry , Zak, Rochelle , Alessi, Cathy , Boehlecke, Brian, Chesson, Andrew L., Friedman, Leah, Owens, Judith , Pancer, Jeffrey, Swick, Todd J. , Morgenthaler, Timothy I. , Kapur, Vishesh K. , Maganti, Rama

Mayo Clinic

Sleep | February 5, 2017 | Volume: 31 | Issue: 1 | Pages: 141-147

10.1093/sleep/31.1.141 | PMID 18220088 Get It

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
Kommoss, Stefan , Winterhoff, Boris , Oberg, Ann L. , Konecny, Gottfried E. , Riska, Shaun M., Fan, Jian-Bing, April, Craig, Shridhar, Viji , Kommoss, Friedrich, Hilpert, Felix , Mahner, Sven� , Baumann, Klaus , Schroeder, W., Burges, Alexander , Canzler, Ulrich , Chien, Jeremy , Embleton-Thirsk, Andrew , Parmar, Mahesh , Kaplan, Richard , Perren, Timothy , Hartmann, Lynn C. , Goode, Ellen L. , Dowdy, Sean C. , Pfisterer, Jacobus , Wang, Chen , Maurer, Matthew J. , Bois, Andreas du , Chien, Jeremey , Kaplan, Richard

Mayo Clinic

Clinical Cancer Research | February 3, 2017 | Volume: 23 | Issue: 14 | Pages: 3794-3801

10.1158/1078-0432.ccr-16-2196 | PMID 28159814 Get It

Abstract Purpose: Recent progress in understanding the molecular biology of epithelial ovarian cancer has not yet translated into individualized treatment for these women or improvements in their disease outcome. Gene expression has been utilized to identify distinct molecular subtypes, but there have been no reports investigating whether or not molecular subtyping is predictive of response to bevacizumab in ovarian cancer. Experimental Design: DASL gene expression arrays were performed on FFPE tissue from patients enrolled on the ICON7 trial. Patients were stratified into four TCGA molecular subtypes. Associations between molecular subtype and the efficacy of randomly assigned therapy with bevacizumab were assessed. Results: Molecular subtypes were assigned as follows: 122 immunoreactive (34%), 96 proliferative (27%), 73 differentiated (20%), and 68 mesenchymal (19%). In univariate analysis patients with tumors of proliferative subtype obtained the greatest benefit from bevacizumab with a median PFS improvement of 10.1 months [HR, 0.55 (95% CI, 0.34–0.90), P = 0.016]. For the mesenchymal subtype, bevacizumab conferred a nonsignificant improvement in PFS of 8.2 months [HR 0.78 (95% CI, 0.44–1.40), P = 0.41]. Bevacizumab conferred modest improvements in PFS for patients with immunoreactive subtype (3.8 months; P = 0.08) or differentiated subtype (3.7 months; P = 0.61). Multivariate analysis demonstrated significant PFS improvement in proliferative subtype patients only [HR, 0.45 (95% CI, 0.27–0.74), P = 0.0015]. Conclusions: Ovarian carcinoma molecular subtypes with the poorest survival (proliferative and mesenchymal) derive a comparably greater benefit from treatment that includes bevacizumab. Validation of our findings in an independent cohort could enable the use of bevacizumab for those patients most likely to benefit, thereby reducing side effects and healthcare cost. Clin Cancer Res; 23(14); 3794–801. ©2017 AACR.
AUA White Paper on Nonneurogenic Chronic Urinary Retention: Consensus Definition, Treatment Algorithm, and Outcome End Points
Stoffel, John T. , Peterson, Andrew C. , Sandhu, Jaspreet S. , Wei, John T., Lightner, Deborah J., Suskind, Anne M. , Stoffel, John T

Mayo Clinic

Journal of Urology | February 3, 2017 | Volume: 198 | Issue: 1 | Pages: 153-160

10.1016/j.juro.2017.01.075 | PMID 28163030 Get It

The Lung Cancer Microbiota and Adjacent Healthy Lung Tissue Microbiota
Haupert, Richard, Gould, Trevor J. , Reilly, Cavan, Wendt, Christine , Pragman, Alexa A. , Sandri, Brian J. , Limper, Andrew H.

Mayo Clinic

Open Forum Infectious Diseases | February 2, 2017 | Volume: 3 | Issue: suppl_1 | Pages: No page available

10.1093/ofid/ofw172.1781 Get It

Risk of Hypertension among First-Time Symptomatic Kidney Stone Formers
Kittanamongkolchai, Wonngarm , Mara, Kristin C. , Mehta, Ramila A. , Vaughan, Lisa E. , Đenić, Aleksandar , Knoedler, John, Knoedler, John J., Enders, Felicity , Lieske, John C. , Rule, Andrew D. , Denic, Aleksandar , Mara, Kristin C

Mayo Clinic

Clinical Journal of the American Society of Nephrology | February 1, 2017 | Volume: 12 | Issue: 3 | Pages: 476-482

10.2215/cjn.06600616 | PMID 28148559 Get It

Background and objectives Prior work has suggested a higher risk of hypertension in kidney stone formers but lacked disease validation and adjustment for potential confounders. Certain types of stone formers may also be at higher risk of hypertension. Design, setting, participants, & measurements In our study, incident symptomatic stone formers in Olmsted County from 2000 to 2011 were manually validated by chart review and age and sex matched to Olmsted County controls. We followed up patients through November 20, 2015. Hypertension was also validated by manual chart review, and the risk of hypertension in stone formers compared with controls was assessed both univariately and after adjusting for comorbidities. The risk of hypertension among different subtypes of stone formers was also evaluated. Results Among 3023 coded stone formers from 2000 to 2011, a total of 1515 were validated and matched to 1515 controls (mean age was 45 years old, and 56% were men). After excluding those with baseline hypertension (20% of stone formers and 18% of controls), 154 stone formers and 110 controls developed hypertension. Median follow-up time was 7.8 years in stone formers and 9.6 years in controls. Stone formers were found to have a higher risk of hypertension compared with controls (hazard ratio, 1.50; 95% confidence interval, 1.18 to 1.92), even after adjusting for age, sex, body mass index, serum creatinine, CKD, diabetes, gout, coronary artery disease, dyslipidemia, tobacco use, and alcohol abuse (hazard ratio, 1.58; 95% confidence interval, 1.12 to 2.21). Results were similar after excluding patients who were ever on a thiazide diuretic (hazard ratio, 1.65; 95% confidence interval, 1.16 to 2.38). Stone composition, radiographic stone burden, number of subsequent stone events, and stone removal surgeries were not associated with hypertension ( P >0.05 for all). Conclusions The risk of hypertension was higher after the first symptomatic kidney stone event. However, kidney stone severity, type, and treatment did not associate with hypertension.
Rapid Phenotypic Antibiotic Susceptibility Testing Using Forward-Angle Laser Light Scattering
Tomaras, Andrew P., Norgan, Andrew P.

Mayo Clinic

Open Forum Infectious Diseases | February 1, 2017 | Volume: 3 | Issue: suppl_1 | Pages: No page available

10.1093/ofid/ofw172.43 Get It

Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) Quantification in Bronchoalveolar Lavage Fluid Collected From Immunocompromised Patients With CMV Pneumonia
Germer, Jeffrey J., Lahr, Brian D. , Binnicker, M. J., Yao, Joseph D. , Beam, Elena , Limper, Andrew H. , Razonable, Raymund R.

Mayo Clinic

Open Forum Infectious Diseases | February 1, 2017 | Volume: 3 | Issue: suppl_1 | Pages: No page available

10.1093/ofid/ofw194.18 Get It

P127 RNAi screening to identify genes essential for myofibroblast activation.
Oh, Raymond , Haak, Andrew J. , Tschumperlin, Daniel J.

Mayo Clinic

QJM: An International Journal of Medicine | January 31, 2017 | Volume: 109 | Issue: suppl_1 | Pages: S65-S65

10.1093/qjmed/hcw120.028 Get It

Rosai-Dorfman Disease: Manifestations Outside of the Head and Neck
Mar, Winnie A. , Yu, Jonathan H., Knuttinen, Martha Gracia, David, Odile , Wilbur, Andrew C., Menias, Christine O. , Horowitz, Jeanne M

Mayo Clinic

American Journal of Roentgenology | January 31, 2017 | Volume: 208 | Issue: 4 | Pages: 721-732

10.2214/ajr.15.15504 | PMID 28140608 Get It

Workshop on imaging science development for cancer prevention and preemption
Kelloff, Gary J. , Sullivan, Daniel C. , Baker, Houston, Clarke, Lawrence, Nordstrom, Robert J. , Tatum, James L. , Dorfman, Gary S., Berg, Christine D. , Birrer, Michael J. , Tempero, Margaret A. , Higley, Howard R., Petty, Brenda Gumbs, Sigman, Caroline C. , Ginsberg, Gregory G. , Dannenberg, Andrew J. , Hawk, Ernest T. , Messing, Edward M. , Grossman, H. Barton, Griebel, Donna, Henson, Donald E., Fabian, Carol J. , Zujewski, Jo Anne , Hayes, Wendy, Klein, Eric A. , Ocak, İclal , Tempany, Clare M. , Shtern, Faina, Parnes, Howard L. , Gómez, Jorge , Srivastava, Sudhir , Lam, Stephen , Seibel, Eric J. , Massion, Pierre P. , McLennan, Geoffrey, Burt, Randall W., Hoffman, John M. , El‐Deiry, Wafik S. , Papadimitrakopoulou, Vali, Veltri, Robert W., Solomon, Diane, Viner, Jaye L., Stratton, Steven P. , Rajadhyaksha, Milind , Dhawan, Atam P. , Jacobs, Paula , Pomper, Martin G. , Maley, Carlo C. , Sharma, Prateek , Wax, Adam , Harisinghani, Mukesh G. , Bigio, Irving J. , Ferrara, Katherine W. , Fantini, Sergio , Schnall, Mitchell D. , Zujewski, Jo Anne , Marzo, Angelo M. De , Ketterling, Jeffrey A. , Szabó, Éva , Cleary, Kevin , Suh, Robert D. , Pfeiffer, Ruth M. , Roy, Hemant K. , Wang, Thomas J. , Limburg, Paul J. , Hittelman, Walter N. , MacAulay, Calum E. , Jerónimo, José , Richards‐Kortum, Rebecca , Johnson, Karen A. , Klein, Eric A

Mayo Clinic

Cancer Biomarkers | January 31, 2017 | Volume: 3 | Issue: 1 | Pages: 1-33

10.3233/cbm-2007-3101 | PMID 17655039 Get It